For instance, MAD2L2 was overexpressed in glioma, epithelial ovarian cancer, and breast cancer (Feng et al., 2016; Niimi et al., 2014; Zhao et al., 2011), while inactivation of MAD2L2 sensitized nasopharyngeal carcinoma cells to DNA‐damaging agents (Cheung et al., 2006). This evidence concerns the gene MAD2L2 and glioma.